Brightseed is a technology company.
Brightseed has raised $95.0M across 2 funding rounds.
Brightseed has raised $95.0M in total across 2 funding rounds.
Brightseed has raised $95.0M in total across 2 funding rounds.
Brightseed's investors include Gabriel Ruimy, Brkfst Club, Main Sequence Ventures, Mayfield, McWin Capital Partners, NEO, SOSV, UpHonest Capital, Vamos Ventures, Gary Hirshberg, Hadi Partovi, Scott Banister.
Brightseed is a biotechnology company founded in 2017 and headquartered in San Francisco, California, that develops AI-powered technology to discover hidden bioactive compounds in plants for applications in human health, nutrition, and wellness.[1][2] It serves industries like food, supplements, and pharmaceuticals by unlocking plant-based ingredients that address health challenges, such as enabling healthier futures through novel compounds revealed by its AI platform.[1][2][3] The company has raised $120.8 million in funding, employs 10-100 people, and shows growth momentum through partnerships with investors like Temasek and a leadership team driving commercialization of AI-discovered bioactives.[1][2]
Brightseed was co-founded in 2017 by Lee Chae (CTO), Sofia Elizondo (COO), Philip Dickinson, and Jim Flatt (CEO), who brought expertise in technology, operations, and biotech to pioneer AI-driven discovery of plant compounds.[1][2] The idea emerged from recognizing nature's untapped potential, using computational biology and machine learning to illuminate connections between plants and human health—addressing the limitations of traditional screening methods.[1][3] Early traction came from securing significant venture funding and building a team under CEO Jim Flatt, positioning it as a leader in AI-biotech innovation without acquisition or IPO to date.[1][2]
Brightseed stands out in biotech through these key strengths:
Brightseed rides the AI-biotech convergence trend, where machine learning decodes nature's complexity to fuel precision nutrition and personalized health amid rising demand for plant-based alternatives to synthetic drugs.[1][2][3] Timing is ideal as global focus on sustainability, chronic disease prevention, and clean-label ingredients intensifies post-pandemic, with market forces like regulatory support for natural bioactives and investor interest in healthtech (e.g., comparables like Virta Health or Ro) propelling growth.[2] It influences the ecosystem by democratizing access to plant intelligence, partnering with food/pharma giants to shift industries toward AI-accelerated, nature-positive innovation.
Brightseed is poised for expansion by scaling AI-discovered compounds into commercial products, potentially through more partnerships or pre-IPO liquidity events via platforms tracking its valuation.[2] Trends like AI advancements in biology, rising plant-based demand, and sustainability mandates will shape its path, evolving its influence from discovery pioneer to key supplier in a $100B+ functional ingredients market. As biotech matures, expect Brightseed to deepen ecosystem impact, illuminating nature's role in healthier futures—just as its technology reveals hidden compounds in plants.
Brightseed has raised $95.0M across 2 funding rounds. Most recently, it raised $68.0M Series B in May 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2022 | $68.0M Series B | Gabriel Ruimy, Brkfst Club, Main Sequence Ventures, Mayfield, McWin Capital Partners, NEO, SOSV, UpHonest Capital, Vamos Ventures, Gary Hirshberg, Hadi Partovi, Scott Banister | |
| Sep 1, 2020 | $27.0M Venture Round | Brick & Mortar Ventures, S3 Ventures |